Mi Jun Keng
Mi Jun Keng
Mi Jun joined the Health Economics Research Centre (HERC) in October 2016. She was involved in health economic evaluation alongside the REVEAL trial. As part of this work, she developed a prognostic model to predict secondary cardiovascular risk in well-managed patients with established atherosclerotic disease. For a separate project, she looked at how achieving treatment targets for diabetes patients impact health outcomes and healthcare costs.
Mi Jun’s research interest is in the development and application of decision-analytics models for healthcare research. She is currently pursuing her DPhil to work on developing a framework to model lifetime outcomes for diabetes patients using data from the ASCEND trial. The ASCEND trial will also provide an interesting case study to apply the framework developed, to bring together evidence on benefits and harms related to aspirin use. One aspect of this work will be to re-evaluate the cardiovascular benefits and bleeding risks related to aspirin use from the patient’s perspective.
Mi Jun graduated with an MSc in Management Science (Operational Research) from the London School of Economics and Political Science (LSE) in 2016, and a BSc (Hons) in Mathematical Sciences from Nanyang Technological University (NTU) in 2014.
Decrements in health‐related quality of life associated with adverse events in people with diabetes
Keng MJ. et al, (2021), Diabetes, Obesity and Metabolism
How valid are projections of the future prevalence of diabetes? Rapid reviews of prevalence-based and Markov chain models and comparisons of different models' projections for England.
Bevan G. et al, (2020), BMJ Open, 10
Impact of achieving primary care targets in Type 2 diabetes on health outcomes and healthcare costs
Keng MJ. et al, (2019), Diabetes, Obesity and Metabolism
Impact of variation in Type 2 diabetes care on health outcomes and healthcare costs
Keng MJ. et al, (2019), DIABETIC MEDICINE, 36, 161 - 161